

Special Issue

Personalized Gastric Cancer Treatment: Recent Progress and Future Perspectives

Message from the Guest Editor

The treatment paradigm in patients with gastric cancer has changed drastically in recent years. In the metastatic setting, based on biomarker testing, we have many approved combination regimens in the first-line setting, including agents targeting HER2 (e.g., trastuzumab), CLDN18.2 (e.g., zolbetuximab), PD-L1 CPS (e.g., pembrolizumab, nivolumab, and tislelizumab), and MSI-H (e.g., pembrolizumab, nivolumab/ipilimumab, and dostarlimab). In the perioperative setting, we are seeing positive results with moving agents to earlier stages, as shown in the recently reported MATTERHORN study where durvalumab was combined with systemic chemotherapy. Despite our success, there remains an unmet need to improve outcomes for patients, as our current treatments risk high recurrence rates, toxicity, and persistently low survival outcomes. Therefore, this Special Issue aims to collate high-quality studies, including original research and reviews, exploring the association of biomarkers with gastric cancer outcomes.

Guest Editor

Dr. Gagandeep Brar

Division of Hematology & Oncology, City of Hope, Duarte, CA 91010, USA

Deadline for manuscript submissions

10 August 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/255102

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).